East Tallinn Central Hospital, Oncology Center, Ravi St 18, 10138 Tallinn, Estonia.
National Institute for Health Development, Department of Epidemiology and Biostatistics, Hiiu St 42, 11619 Tallinn, Estonia; West Tallinn Central Hospital, Womens' Clinic, Paldiski St 68, 10617 Tallinn, Estonia.
Cancer Epidemiol. 2019 Oct;62:101566. doi: 10.1016/j.canep.2019.101566. Epub 2019 Jul 19.
Corpus uteri cancer has become the fourth most common female cancer in Europe. In Estonia, the prevalence of obesity is increasing, and corpus uteri cancer survival has been relatively low. The aim of the study was to evaluate incidence, mortality and survival trends of corpus uteri cancer in Estonia by age, stage and histological subtypes with an emphasis on surgical treatment.
Estonian Cancer Registry data on incident cases of corpus uteri cancer were used to examine incidence trends (1995-2016) and calculate relative survival ratios (RSR) (1996-2016). Cases were classified by morphology and FIGO stage. Causes of Death Registry data were used to analyse corrected mortality (1995-2017).
A total of 4281 cases were diagnosed in 1996-2016. A significant increase was seen in age-standardized incidence from 2009, while mortality remained stable throughout the study period. Significant increases were observed for type I cancers and age groups ≥65 years. Overall age-standardized 5-year RSR improved from 70% in 1996-2002 to 78% in 2010-2016. Survival increased for type I cancers, all age groups and all stages (significantly for stage IV). The proportion of surgically treated cases increased significantly from 85% to 89%, with the largest increases seen in older age groups and later stages.
The rising corpus uteri cancer incidence in Estonia is driven by the type I cancer trend. Survival gain for later stages and older age groups likely reflected more frequent surgical treatment. To reduce mortality, further efforts are necessary to ensure appropriate care for all patients.
子宫体癌已成为欧洲第四大常见女性癌症。在爱沙尼亚,肥胖症的患病率正在上升,而子宫体癌的存活率相对较低。本研究旨在评估爱沙尼亚子宫体癌的发病率、死亡率和生存趋势,按年龄、分期和组织学亚型进行评估,并重点关注手术治疗。
利用爱沙尼亚癌症登记处子宫体癌发病数据,研究发病率趋势(1995-2016 年)并计算相对生存率(RSR)(1996-2016 年)。病例按形态学和 FIGO 分期分类。死因登记处的数据用于分析校正死亡率(1995-2017 年)。
1996-2016 年共诊断出 4281 例病例。标准化发病率从 2009 年开始显著上升,而研究期间死亡率保持稳定。I 型癌症和≥65 岁年龄组的发病率显著增加。总体标准化 5 年 RSR 从 1996-2002 年的 70%提高到 2010-2016 年的 78%。I 型癌症、所有年龄组和所有分期的生存率均有所提高(IV 期显著提高)。手术治疗病例的比例从 85%显著增加到 89%,在老年组和晚期阶段增加幅度最大。
爱沙尼亚子宫体癌发病率的上升主要归因于 I 型癌症的趋势。晚期和老年组生存率的提高可能反映了更频繁的手术治疗。为了降低死亡率,需要进一步努力确保所有患者都能得到适当的护理。